Biotek-snakken — September 2023
-
Biovica signs US agreement with leading healthcare provider in Arizona - Biovica International AB
Biovica today announces that the company has entered into a commercial agreement with a leading healthcare provider that operates more than 30 hospital laboratories, primarily located in Arizona. The agreement will ensure access to DiviTum® TKa for patients across the partners extensive network covering the southwest region of the United States. This agreement marks Biovica’s […]
Biovica International AB (biovica.com)
-
Jeg har haft Calliditas Therapeutics i kikkerten i lang tid, men den kom aldrig ned under kurs 90 som var mit target. Så kom den på listen hos DI og steg den en del og faldt lidt tilbage. I går løb den endeligt helt væk pga. dårligt nyt fra en konkurrent (Traveres). Den streg voldsomt men faldt en del tilbage og jeg nåede at få en lille position lige før luk i omkring kurs 103.
-
Calliditas Therapeutics
Link til deres hjemmeside:
Calliditas Therapeutics AB
Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas Therapeutics AB (www.calliditas.se)
Q2 2023 REPORT:
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind